No patients with focal and segmental glomerulosclerosis responded to treatment.<h4>Lessons learned</h4>Higher rate of adverse events than previously reported with synthetic adrenocorticotropic hormone and uncertain treatment efficacy. Here, POMC is linked to focal segmental glomerulosclerosis.